Loading
Evommune, Inc. is a United States-based clinical-stage biotechnology company dedicated to advancing novel therapeutic solutions. Their primary focus lies in addressing the underlying mechanisms of chronic inflammatory diseases. Initial clinical development efforts are concentrated on conditions such as chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. The company's investigational portfolio features EVO756, which is being developed for the treatment of chronic spontaneous urticaria (CSU) and atopic dermatitis (AD), and EVO301, intended for atopic dermatitis (AD) and ulcerative colitis (UC). Established in 2020, Evommune operates from its headquarters in Palo Alto, California.
Previous close
$10.54
−$0.02 · -0.19%
Regular session · ET · Market data may be delayed.
Evommune, Inc. is a United States-based clinical-stage biotechnology company dedicated to advancing novel therapeutic solutions. Their primary focus lies in addressing the underlying mechanisms of chronic inflammatory diseases. Initial clinical development efforts are concentrated on conditions such as chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. The company's investigational portfolio features EVO756, which is being developed for the treatment of chronic spontaneous urticaria (CSU) and atopic dermatitis (AD), and EVO301, intended for atopic dermatitis (AD) and ulcerative colitis (UC). Established in 2020, Evommune operates from its headquarters in Palo Alto, California.
Day range
Current $10.54
52-week range
Current $10.54
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
73
Undervalued
Sentiment
56
Mixed
Risk
67
High Risk
Momentum
21
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Evommune, Inc. is a United States-based clinical-stage biotechnology company dedicated to advancing novel therapeutic solutions. Their primary focus lies in addressing the underlying mechanisms of chronic inflammatory diseases. Initial clinical development efforts are concentrated on conditions such as chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. The company's investigational portfolio features EVO756, which is being developed for the treatment of chronic spontaneous urticaria (CSU) and atopic dermatitis (AD), and EVO301, intended for atopic dermatitis (AD) and ulcerative colitis (UC). Established in 2020, Evommune operates from its headquarters in Palo Alto, California.
Day range
Current $10.54
52-week range
Current $10.54
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | 13M USD | 7M USD | 5M USD |
| Cost of goods sold | — | 1.29M USD | 1M USD |
| Gross profit | 13M USD | 5.71M USD | 4M USD |
| Research and development | 74.04M USD | 64.24M USD | 32M USD |
| Selling, general, and administrative | 20.03M USD | 11.48M USD | 9.85M USD |
| Operating expenses | 94.07M USD | 75.73M USD | 41.85M USD |
| Interest income | 3.32M USD | 3.24M USD | 3.86M USD |
| Interest expense | — | 34K USD | 58K USD |
| Depreciation and amortization | 1.39M USD | 1.29M USD | 1M USD |
| Operating income | −81.07M USD | −70.01M USD | −37.85M USD |
| Net income | −68.87M USD | −66.81M USD | −34.05M USD |
Company facts updated Sep 13, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI8.31M0.00%2.3T USD0.03%$376.31+0.82%
iShares Russell 2000 ETFIWM3.51M0.00%77.55B USD0.19%$288.89+0.41%
Fidelity Enhanced Small Cap ETFFESM1.54M0.02%6.49B USD0.28%$46.36+0.78%
Vanguard Extended Market ETFVXF1.42M0.00%93.7B USD0.05%$237.76+0.68%
iShares Russell 2000 Growth ETFIWO1.29M0.01%14.32B USD0.24%$367.63+0.54%
Vanguard Russell 2000 ETFVTWO804.67K0.00%17.4B USD0.06%$116.76+0.36%
Schwab U.S. Small-Cap ETFSCHA562.07K0.00%22.43B USD0.03%$33.79+0.42%
ALPS Medical Breakthroughs ETFSBIO522.6K0.22%232.86M USD0.50%$63.29-0.80%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMFidelity Enhanced Small Cap ETFFESMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAALPS Medical Breakthroughs ETFSBIOAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
